DOCTOR'S VIEW ARCHIVE
COX-2 Inhibitors Dilemma
Vioxx, Celebrex, Bextra What Patients Should Do
Medical Author: William C. Shiel, Jr., MD, FACP, FACR
Medical Editor: Jay W. Marks, MD
The recent withdrawal of Vioxx from the market
(September, 2004) has resulted in one of the most tumultuous times in history
for the pharmaceutical industry, patients, and doctors. At the time of its
withdrawal, Vioxx was one of the most widely used medications in the world. The
fallout has left the pharmaceutical industry on edge at a minimum, left patients
worried and wondering whom to trust, and left doctors out on a limb faced with
controversial research data to
review with their patients.
In this article, I hope to: (1) clarify issues by using
the current dilemma of the COX-2 inhibitor drugs [(rofecoxib) Vioxx, (celecoxib)
Celebrex, and (valdecoxib) Bextra] NOTE: April 7, 2005, Pfizer agreed to suspend sales and marketing of Bextra in the U.S., pending further discussions with the with the FDA. For more information, please read the
FDA press release.
, as a background; and (2) present general
guidelines as to what patients should do in response to having their medication
withdrawn from the market or even hearing of
potential risks of their medications that are reported in the media.